BioSpace News Archive

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, announced that its Board of Directors has declared a quarterly cash dividend to holders of its 6.250% Series A Mandatory Convertible Preferred Stock of $0.78 per share at a rate per share of 1.560%, payable on February 15, 2021 to holders of record on February 1, 2021.

Conformis, Inc. (NASDAQ:CFMS) and SITES Medical, a firm dedicated to inventing and de-risking new orthopedic medical device technologies, today announced they have entered into a non-exclusive development and supply agreement. The companies will work together to incorporate SITES Medical’s proprietary OsteoSync Ti Technology into future Conformis’ cementless total knee replacement products. “We are excited to be part

Researchers at the University of Maryland School of Medicine (UMSOM) have found promising results in pre-clinical studies for a new experimental vaccine against COVID-19 made by Novavax.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that three oral presentations and ten posters highlighting its development programs for Lysosomal Disorders will be included at the 17th Annual WORLD Symposium ™ 2021 , to be held virtually February 8-12, 2021.

- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn’s & Colitis Congress® to be held from today January 21-24, 2021 .

MJ Biotech Inc. is pleased to announce that it’s subsidiary New England Biotech’s partner Genesis Botanical, has begun construction of the CBD Extraction facility after securing a location.

Crescita Therapeutics Inc. and, a commercial dermatology, announced that Laboratoires FILLMED has submitted a New Medical Device License application for the ART FILLER® range of products.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (minocycline) topical foam, 4% and ZILXI® (minocycline) topical foam, 1.5%

Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, provides the following summary of today’s upcoming presentation by Cocrystal President Sam Lee, Ph.D. at the virtual 3rd Annual reimagine Health Research Symposium

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,889,587,